首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 再生醫學細胞療法基因療法

亞太地區細胞和基因治療製造服務市場預測至 2030 年 - 區域分析 - 按類型、適應症（癌症、骨科等）、應用（臨床製造和商業製造）和最終用戶

市場調查報告書

商品編碼

1452619

亞太地區細胞和基因治療製造服務市場預測至 2030 年 - 區域分析 - 按類型、適應症（癌症、骨科等）、應用（臨床製造和商業製造）和最終用戶

Asia Pacific Cell and Gene Therapy Manufacturing Services Market Forecast to 2030 - Regional Analysis - by Type, Indication (Cancer, Orthopedics, and Others), Application (Clinical Manufacturing and Commercial Manufacturing), and End User

出版日期: 2024年01月15日 | 出版商:

The Insight Partners | 英文 112 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

亞太細胞和基因治療製造服務市場預計將從2022年的10.0742億美元成長到2030年的36.1318億美元。預計2022年至2030年CAGR為17.3%。

細胞和基因治療製造服務的自動化推動亞太細胞和基因治療製造服務市場

在細胞和基因治療製造中涵蓋自動化將降低污染風險、提高一致性並降低生產成本。 Lonza Cocoon 和 Miltenyi 的 CliniMACS Prodigy 系統是市場上可實現自動化的一些設備。這些產品旨在實現單一系統內 CAR-T 流程的大多數連續單元操作的自動化。對細胞和基因治療的需求不斷成長，使得全球範圍內細胞和基因治療產品的生產從小批量生產轉向大批量生產。除了不斷增加的研究活動外，細胞和基因治療從學術和臨床環境到大規模生產和商業化的發展也推動了商業製造對自動化的需求。 2020 年 7 月，Thermo Fisher Scientific Inc. 和 Lyell Nutrition 合作開發和製造程序，為癌症患者設計有效的細胞療法。根據這項合作關係，兩家公司的目標是提高 T 細胞的能力，並支持開發符合現行良好生產規範 (cGMP) 的綜合平台（系統和軟體）以及試劑、耗材和儀器。因此，自動化正在成為亞太細胞和基因治療製造服務市場的新趨勢。

亞太地區細胞與基因治療製造服務市場概況

亞太地區包括中國、日本、印度、澳洲、韓國和亞太其他國家。亞太地區是細胞和基因治療領域的領先地區之一，有多個國家參與投資這些療法的研究和開發。在細胞和基因療法方面，日本是亞太地區的領導者之一。 2014年，日本是第一個批准細胞治療產品（一種治療黃斑部病變的藥物）的國家。此後，其他幾種細胞和基因療法也已在該國獲得批准，包括用於白血病和淋巴瘤的 CAR-T 療法。

中國於2003年成為第一個批准基因療法的國家，此後細胞和基因療法的發展在全球迅速發展，其治療潛力也隨之飆升。中國政府進行了多項監管改革，以促進細胞和基因療法的規範發展。根據 2021 年《自然》雜誌發表的一項研究，全球超過 50% 的細胞治療試驗都在中國進行。目前，中國正在進行近400個以血液學、腫瘤學和實體瘤為中心的CAR-T試驗。隨著復星凱特的Yescarta和JW Therapeutics的Relma-cel於2021年獲得國家藥品監督管理局（NMPA）批准，中國的細胞治療正進入一個新時代。由於成本較低和患者人數較多，多家跨國公司已轉移到該地區以利用這些因素。

亞太地區細胞及基因治療製造服務市場收入及 2030 年預測（百萬美元）

亞太地區細胞和基因治療製造服務市場細分

亞太細胞和基因治療製造服務市場按類型、適應症、應用、最終用戶和國家/地區進行細分。

根據類型，亞太細胞和基因治療製造服務市場分為細胞治療和基因治療。 2022年，細胞治療領域在亞太細胞和基因治療製造服務市場中佔據更大佔有率。細胞治療部分進一步分為自體細胞治療和同種異體細胞治療。基因治療部分進一步細分為病毒載體和非病毒載體。

根據跡象，亞太細胞和基因治療製造服務市場分為癌症、骨科等。 2022年，癌症領域在亞太細胞和基因治療製造服務市場中佔據最大佔有率。

根據應用，亞太細胞和基因治療製造服務市場分為臨床製造和商業製造。 2022年，商業製造領域在亞太細胞和基因治療製造服務市場中佔據最大佔有率。

根據最終用戶，亞太細胞和基因治療製造服務市場分為製藥和生物技術公司和合約研究組織（CRO）。 2022年，製藥和生物技術公司部門在亞太細胞和基因治療製造服務市場中佔據更大佔有率。

按國家/地區分類，亞太地區細胞和基因治療製造服務市場分為中國、日本、印度、澳洲、韓國和亞太地區其他地區。 2022年，中國在亞太細胞和基因治療製造服務市場中佔據最大佔有率。

Catalent Inc、Charles River Laboratories International Inc、FUJIFILM Holdings Corp、Lonza Group AG、Merck KgaA、Nikon Corp、Takara Bio Inc、Thermo Fisher Scientific Inc 和 WuXi AppTec Co Ltd 是亞太地區的一些領先公司。基因治療製造服務市場。

Incorporating automation in cell and gene therapy manufacturing would lead to a reduced risk of contamination, improved consistency, and decreased cost of production. Lonza Cocoon and the CliniMACS Prodigy system from Miltenyi are a few of the devices available in the market to enable automation. These products have been designed to enable the automation of most sequential unit operations for a CAR-T process within a single system. The rising demand for cell and gene therapies has shifted the production of cell and gene therapy products from a small-volume process to a large-volume process worldwide. In addition to the increasing research activities, the evolution of cell and gene therapy from an academic and clinical setting to mass production and commercialization has propelled the demand for automation in commercial manufacturing. In July 2020, Thermo Fisher Scientific Inc. and Lyell Immunopharma partnered to develop and manufacture processes to design effective cell therapies for cancer patients. Under this partnership, the companies aim to improve the capability of T-cells and support the development of an integrated current good manufacturing practice (cGMP) compliant platform (system and software), along with reagents, consumables, and instruments. Thus, automation is emerging as a new trend in the Asia Pacific cell and gene therapy manufacturing services market.

Asia Pacific Cell and Gene Therapy Manufacturing Services Market Overview

Asia Pacific region comprises of China, Japan, India, Australia, South Korea, and Rest of Asia Pacific countries. The Asia Pacific region is one of the leading regions in the field of cell and gene therapy, with several countries which are involved in the investing in research and development of these therapies. Japan is one of the leaders in the Asia Pacific region when it comes to cell and gene therapies. In 2014, Japan was the first country to approve a cell therapy product, a treatment for macular degeneration. Several other cell and gene therapies have been approved in the country since then, including the CAR-T for leukemia and lymphoma.

China is the first country to approve a gene therapy in 2003, since then cell and gene therapy development has advanced rapidly worldwide, and their therapeutic potential has soared. China's government has conducted several regulatory reforms to promote normative development of cell and gene therapies. According to a study published in Nature in 2021, China is home to more than 50% of all cell therapy trials across the world. Currently, China has nearly 400 ongoing CAR-T trials centered on hematology and oncology and solid tumors. Cell therapy in China is entering a new era with the approval of Fosun Kite's Yescarta and JW Therapeutics' Relma-cel in 2021 from the National Medical Products Administration (NMPA). Due to lower costs and larger patient populations, several multinational companies have moved to the region to take advantage of these factors.

Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Cell and Gene Therapy Manufacturing Services Market Segmentation

The Asia Pacific cell and gene therapy manufacturing services market is segmented into type, indication, application, end user, and country.

Based on type, the Asia Pacific cell and gene therapy manufacturing services market is bifurcated into cell therapy and gene therapy. In 2022, the cell therapy segment registered a larger share in the Asia Pacific cell and gene therapy manufacturing services market. The cell therapy segment is further segmented into autologous and allogenic. The gene therapy segment is further segmented into viral and non-viral vector.

Based on indication, the Asia Pacific cell and gene therapy manufacturing services market is segmented into cancer, orthopedics, and others. In 2022, the cancer segment registered the largest share in the Asia Pacific cell and gene therapy manufacturing services market.

Based on application, the Asia Pacific cell and gene therapy manufacturing services market is segmented into clinical manufacturing and commercial manufacturing. In 2022, the commercial manufacturing segment registered the largest share in the Asia Pacific cell and gene therapy manufacturing services market.

Based on end user, the Asia Pacific cell and gene therapy manufacturing services market is bifurcated into pharmaceutical and biotechnology companies and contract research organization (CROs). In 2022, the pharmaceutical and biotechnology companies segment registered a larger share in the Asia Pacific cell and gene therapy manufacturing services market.

Based on country, the Asia Pacific cell and gene therapy manufacturing services market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. In 2022, China registered the largest share in the Asia Pacific cell and gene therapy manufacturing services market.

Catalent Inc, Charles River Laboratories International Inc, FUJIFILM Holdings Corp, Lonza Group AG, Merck KgaA, Nikon Corp, Takara Bio Inc, Thermo Fisher Scientific Inc, and WuXi AppTec Co Ltd are some of the leading companies operating in the Asia Pacific cell and gene therapy manufacturing services market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Key Industry Dynamics

4.1 Key Market Drivers:
- 4.1.1 Increase in Number of Approval of Cell and Gene Therapies
- 4.1.2 Increasing Popularity of Outsourcing Cell and Gene Therapy Manufacturing
4.2 Market Restraints
- 4.2.1 High Cost of Cell and Gene Therapy Manufacturing
4.3 Market Opportunities
- 4.3.1 Strategic Initiatives by Companies
4.4 Future Trends
- 4.4.1 Automation of Cell and Gene Therapy Manufacturing Services
4.5 Impact Analysis:

5. Cell and Gene Therapy Manufacturing Services Market - Asia Pacific Market Analysis

5.1 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue (US$ Mn), 2022 - 2030

6. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by Type

6.1 Overview
6.2 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
6.3 Cell Therapy
- 6.3.1 Overview
- 6.3.2 Cell Therapy: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.3.2.1 Autologous
    - 6.3.2.1.1 Overview
    - 6.3.2.1.2 Autologous: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.3.2.2 Allogenic
    - 6.3.2.2.1 Overview
    - 6.3.2.2.2 Allogenic: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Gene Therapy
- 6.4.1 Overview
- 6.4.2 Gene Therapy: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.4.2.1 Viral Vector
    - 6.4.2.1.1 Overview
    - 6.4.2.1.2 Viral Vector: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.4.2.2 Non-Viral Vector
    - 6.4.2.2.1 Overview
    - 6.4.2.2.2 Non-Viral Vector: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Analysis and Forecasts to 2030 - by Indication

7.1 Overview
7.2 Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
7.3 Cancer
- 7.3.1 Overview
- 7.3.2 Cancer: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Orthopedics
- 7.4.1 Overview
- 7.4.2 Orthopedics: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Others
- 7.5.1 Overview
- 7.5.2 Others: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by Application

8.1 Overview
8.2 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
8.4 Clinical Manufacturing
- 8.4.1 Overview
- 8.4.2 Clinical Manufacturing: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Commercial Manufacturing
- 8.5.1 Overview
- 8.5.2 Commercial Manufacturing: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by End User

9.1 Overview
9.2 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
9.4 Pharmaceutical and Biotechnology Companies
- 9.4.1 Overview
- 9.4.2 Pharmaceutical & Biotechnology Companies: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
9.5 Contract Research Organizations (CROs)
- 9.5.1 Overview
- 9.5.2 Contract Research Organizations (CROs): Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - Country Analysis

10.1 Overview
- 10.1.1 Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
  - 10.1.1.1 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.1.1 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
    - 10.1.1.1.1.1 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
    - 10.1.1.1.1.2 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    - 10.1.1.1.2 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    - 10.1.1.1.3 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    - 10.1.1.1.4 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  - 10.1.1.2 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.2.1 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
    - 10.1.1.2.1.1 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
    - 10.1.1.2.1.2 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    - 10.1.1.2.2 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    - 10.1.1.2.3 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    - 10.1.1.2.4 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  - 10.1.1.3 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.3.1 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
    - 10.1.1.3.1.1 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
    - 10.1.1.3.1.2 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    - 10.1.1.3.2 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    - 10.1.1.3.3 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    - 10.1.1.3.4 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  - 10.1.1.4 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.4.1 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
    - 10.1.1.4.1.1 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
    - 10.1.1.4.1.2 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    - 10.1.1.4.2 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    - 10.1.1.4.3 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    - 10.1.1.4.4 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  - 10.1.1.5 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.5.1 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
    - 10.1.1.5.1.1 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
    - 10.1.1.5.1.2 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    - 10.1.1.5.2 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    - 10.1.1.5.3 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    - 10.1.1.5.4 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  - 10.1.1.6 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.6.1 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
    - 10.1.1.6.1.1 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
    - 10.1.1.6.1.2 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    - 10.1.1.6.2 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    - 10.1.1.6.3 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    - 10.1.1.6.4 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)

11. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Industry Landscape

11.1 Overview
11.2 Growth Strategies in Asia Pacific Cell and Gene Therapy Manufacturing Services Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Thermo Fisher Scientific Inc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Merck KGaA
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Charles River Laboratories International Inc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Lonza Group AG
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 WuXi AppTec Co Ltd?
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Catalent Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Takara Bio Inc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Nikon Corp
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 FUJIFILM Holdings Corp
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments

簡介目錄圖表

List Of Tables

Table 1. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Segmentation
Table 2. China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 3. China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 4. China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 5. China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 6. China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 7. China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 8. Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 9. Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 10. Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 11. Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million
Table 12. Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 13. Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 14. India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 15. India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 16. India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 17. India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 18. India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 19. India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 20. Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 21. Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 22. Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 23. Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 24. Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 25. Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 26. South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 27. South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 28. South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 29. South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 30. South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 31. South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 32. Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 33. Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 34. Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 35. Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 36. Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 37. Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 38. Recent Organic Growth Strategies in Asia Pacific Cell and Gene Therapy Manufacturing Services Market
Table 39. Recent Inorganic Growth Strategies in the Asia Pacific Cell and Gene Therapy Manufacturing Services Market

List Of Figures

Figure 1. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Segmentation, By Country
Figure 2. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue (US$ Mn), 2022 - 2030
Figure 5. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
Figure 6. Cell Therapy: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Autologous: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Allogenic: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Gene Therapy: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Viral Vector: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Non-Viral Vector: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
Figure 13. Cancer: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Orthopedics: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
Figure 17. Clinical Manufacturing: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Commercial Manufacturing: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
Figure 20. Pharmaceutical & Biotechnology Companies: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Contract Research Organizations (CROs): Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 22. Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Key Region - Revenue (2022) (US$ Million)
Figure 23. Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
Figure 24. China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 26. India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 27. Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 28. South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 29. Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 30. Growth Strategies in Asia Pacific Cell and Gene Therapy Manufacturing Services Market